NASDAQ · Health care

UNITED THERAPEUTICS Corp (UTHR)

UNITED THERAPEUTICS Corp brought in $3.2B of revenue over the twelve months to September 30, 2026, up 1.9% from a year earlier. Net income was $1.2B, a net margin of 38.6%. Operating cash flow minus capital spending left $1B of free cash flow in fiscal 2025. At September 30, 2026 it held $1.2B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.

Watch UTHR in 60 seconds

Price

$588.61

+1.06% on the day · November 10, 2026

52-week range $449.58 to $614.23

Market cap

$25.2B

Revenue (last 12 months)

$3.2B

+1.9% year on year

Net margin

38.6%

P/E

21.1

on FY2025 diluted EPS

Key facts about UNITED THERAPEUTICS Corp

Net worth: UNITED THERAPEUTICS Corp has a market value (market cap) of $25.2B at the latest share price, and shareholders' equity of $6.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $3.2B (+10.6% year on year), with net income of $1.3B. Over the 12 months to September 30, 2026: revenue $3.2B, net income $1.2B.
Cash flow: In fiscal 2025 operations brought in $1.6B of cash; after $520.5M of capital spending, free cash flow was $1B.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: UNITED THERAPEUTICS Corp's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What UNITED THERAPEUTICS Corp does

UNITED THERAPEUTICS Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker UTHR.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$3.2B	$1.5B	$1.3B	$27.86	$1B
2024	$2.9B	$1.4B	$1.2B	$24.64	$1.1B
2023	$2.3B	$1.2B	$984.8M	$19.81	$747.6M
2022	$1.9B	$979.7M	$727.3M	$15.00	$663.7M
2021	$1.7B	$555.9M	$475.8M	$10.06	$477.4M
2020	$1.5B	$593.6M	$514.8M	$11.54	$696.4M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around February 24, 2027.

Estimated from its filing rhythm: 52 weeks after its report of February 25, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where UTHR ranks in Health care

Revenue$3.2B

#88 of 751 in Health care · Top 12%

Revenue growth+10.6%

#275 of 532 in Health care · Bottom 48%

Net margin41.9%

#18 of 544 in Health care · Top 3%

Free cash flow margin32.7%

#19 of 490 in Health care · Top 4%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What UNITED THERAPEUTICS Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 4, 2026
Passive stake changed SCHEDULE 13G/A
November 4, 2026
Quarterly results 8-K
November 4, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 4.1% to $832.5M versus the same quarter last year; diluted EPS $5.71 versus $7.16.
October 22, 2026
Other event 8-K
October 14, 2026
Other event 8-K
September 8, 2026
Material agreement 8-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Passive stake changed SCHEDULE 13G/A
August 5, 2026
Quarterly results 8-K
August 5, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 1.9% to $783.3M versus the same quarter last year; diluted EPS $7.27 versus $6.41.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 9, 2026. Insider transactions on SEC

What is UTHR worth? A DCF from its reported cash flow

Insider trades

What the people running UNITED THERAPEUTICS Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $334.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$334.2M

last 90 days

Net sold

629,528

$334.2M

Date	Insider	What	Shares	Price	Value	Filing
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Exercised optionsindirect	9,500	$117.76	$1.1M	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	109	$560.79	$61.1K	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	2,005	$561.80	$1.1M	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	1,136	$562.87	$639.4K	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	870	$563.85	$490.6K	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	1,776	$564.99	$1M	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	1,742	$565.85	$985.7K	Form 4
November 6, 2026	Rothblatt Martine AChairperson & CEO, Director	Soldpre-planned (10b5-1), indirect	1,021	$566.83	$578.7K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns UTHR

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Vanguard Capital Management13G, passive	5.19%	2,278,348	April 30, 2026

Latest filings below 5%: Martine A. Rothblatt 4% (November 4, 2026); Wellington Management Group LLP 3.2% (August 13, 2026); The Vanguard Group 0% (March 27, 2026).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 878 managers reported a position.

Holder	Shares	Value	Change on quarter
BlackRock, Inc.	5,294,529	$2.87B	-105,120
Avoro Capital Advisors LLC	2,777,777	$1.51B	+147,777
Vanguard Portfolio Management LLC	1,919,429	$1.04B	-84,313
Vanguard Capital Management LLC	1,918,256	$1.04B	-39,283
State Street Corp	1,898,064	$1.03B	+54,101
Renaissance Technologies LLC	1,708,739	$925.8M	-78,280
Wellington Management Group Llp	1,379,025	$747.2M	-885,222
Geode Capital Management, LLC	996,598	$538.9M	-236,431
Jupiter Topco LLC	831,129	$450.1M	new
Norges Bank	694,753	$376.4M	new
Assetmark, Inc	624,068	$338.1M	+8,018
Aqr Capital Management LLC	546,002	$294.6M	-280,224
Dimensional Fund Advisors LP	527,904	$286M	+15,165
Fmr LLC	473,409	$256.5M	-54,937
Invesco Ltd.	473,109	$256.3M	-135,258
Baillie Gifford & Co	467,209	$253.1M	+39,082
Deerfield Management Company, L.P.	457,000	$247.6M	0
Morgan Stanley	436,699	$236.6M	+27,411
Vestal Point Capital, LP	435,000	$235.7M	+360,000
Northern Trust Corp	430,844	$233.4M	-5,722

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

13 insiders reported holding 512,632 shares in total, about $301.7M at the last price.

Holder	Shares	As of
Rothblatt Martine AChairperson & CEO, Director	364,956324,443 held indirectly	November 6, 2026
Mahon Paul AEVP & GENERAL COUNSEL	45,172	November 5, 2026
Giltner RichardDirector	21,884	July 9, 2026
Benkowitz MichaelPRESIDENT AND COO	19,04619,046 held indirectly	March 15, 2026
Edgemond JamesCFO AND TREASURER	18,876	June 22, 2026
Kurzweil RayDirector	13,320	July 9, 2026
Thompson Tommy GDirector	8,480	March 26, 2026
Mesa NildaDirector	5,580	September 14, 2026
Olian Judy D.Director	5,555	July 9, 2026
Causey ChristopherDirector	4,190	March 30, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about UTHR

What does UNITED THERAPEUTICS Corp do?

UNITED THERAPEUTICS Corp is a company in the Health care sector, listed on NASDAQ as UTHR. Its shares trade on NASDAQ under the ticker UTHR.

What is UNITED THERAPEUTICS Corp's net worth?

UNITED THERAPEUTICS Corp has a market value (market cap) of $25.2B at the latest share price, and shareholders' equity of $6.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is UNITED THERAPEUTICS Corp profitable?

Yes. Over the twelve months to September 30, 2026 it reported net income of $1.2B on revenue of $3.2B, a net margin of 38.6%.

How much revenue does UNITED THERAPEUTICS Corp make?

Over the twelve months to September 30, 2026 UNITED THERAPEUTICS Corp reported revenue of $3.2B. That is 1.9% more than a year earlier.

When did UNITED THERAPEUTICS Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.

When is UNITED THERAPEUTICS Corp's next earnings report?

UNITED THERAPEUTICS Corp's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

ROIV

Roivant Sciences Ltd.

INSM

INSMED Inc

ALNY

Alnylam Pharmaceuticals, Inc.

Compare UTHR with

Compare UTHR with any company

Follow UTHR

Get an email when UNITED THERAPEUTICS Corp files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values UNITED THERAPEUTICS Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.